Beloderm Express spray for external use 0.05% 50 ml bottle 1 pc. in Moscow
Pharmacological action: Interacts with specific receptors in the cytoplasm of the cell, the resulting complex penetrates the cell nucleus, binds to DNA and stimulates the synthesis of mRNA, inducing the formation of proteins, incl. lipocortin, mediating cellular effects. In some cells (for example, in lymphocytes) it causes suppression of mRNA. Lipocortin inhibits phospholipase A2, blocks the liberation of arachidonic acid and the biosynthesis of endoperoxides, PGs, and leukotrienes (which contribute to the development of inflammation, allergies and other pathological processes).
Affects all phases of inflammation. The anti-inflammatory effect is due to many factors. One of the leading ones is inhibition of phospholipase A2 with subsequent inhibition of the formation of pro-inflammatory mediators - PG and leukotrienes. In addition, it stabilizes cell membranes, incl. membranes of lysosomes, prevents the release of lysosomal enzymes and reduces their concentration at the site of inflammation. Inhibits the migration of neutrophils and macrophages to the site of inflammation and their phagocytic activity. Improves microcirculation, reduces vascular permeability, causes vasoconstriction of capillaries, and reduces fluid exudation.
The antiallergic effect develops as a result of a decrease in the synthesis and secretion of allergy mediators, inhibition of the release of histamine and other biologically active substances from sensitized mast cells and basophils, a decrease in the number of circulating basophils, suppression of the proliferation of lymphoid and connective tissue, a decrease in the number of T- and B-lymphocytes, mast cells , reducing the sensitivity of effector cells to allergy mediators, suppressing antibody formation, changing the body’s immune response.
The immunosuppressive effect is associated with suppression of the activity of T- and B-lymphocytes, as well as inhibition of the release of cytokines (interleukin-1, interleukin-2, interferon-gamma) from leukocytes and macrophages.
Antishock and antitoxic effects are associated with an increase in blood pressure (due to an increase in the amount of circulating catecholamines, restoration of the sensitivity of adrenergic receptors to catecholamines and vasoconstriction), activation of liver enzymes involved in the metabolism of endo- and xenobiotics.
It has a pronounced effect on all types of exchange. Stimulates gluconeogenesis in the liver, increases blood glucose levels (glucosuria is possible). Accelerates protein catabolism, especially in muscle tissue. Causes a redistribution of fat: increases lipolysis in the tissues of the extremities, promotes the accumulation of fat mainly in the face (moon face), neck, and shoulder girdle. Retains Na+ and water, stimulates the excretion of K+, increases the excretion of Ca+.
With long-term use, it suppresses the function of the hypothalamus-pituitary-adrenal system.
After parenteral (i.m.) and enteral administration, it is rapidly absorbed - the maximum effect (when taken orally) develops after 1–2 hours.
When using a combination of salts in one preparation, betamethasone disodium phosphate is well absorbed from the injection site and has a rapid effect; betamethasone dipropionate has a slower absorption, but provides a long-lasting effect.
When instilled into the conjunctival sac, it penetrates into the intraocular fluid, cornea, iris, choroid, ciliary body, and retina. Systemic absorption may be significant only when used in high doses or with prolonged use in children.
When applied locally to the skin, the intensity of absorption depends on a number of factors: the solvent (polypropylene components improve diffusion), the state of the epidermal barrier (inflammation and skin diseases increase absorption).
Binds to plasma proteins. Easily passes histohematic barriers, including placental ones. Partially excreted in breast milk. Biotransformed mainly in the liver, the resulting metabolites are inactive. Excreted by the kidneys.
Carcinogenicity, mutagenicity, effect on fertility
Long-term animal studies have not been conducted to evaluate the potential carcinogenicity or effects on fertility of topical betamethasone. Betamethasone was genotoxic in vitro
in the chromosomal aberration test on human lymphocytes (with metabolic activation) and
in vivo
in the micronucleus test on mouse bone marrow.
Beloderm Express
Beloderm Express (INN betamethasone) is a long-acting glucocorticosteroid for topical use. Suppresses the functions of white blood cells and tissue monocytes. Prevents the migration of white blood cells into the inflammatory focus. Reduces the ability of monocytes to absorb large macromolecular complexes or corpuscles, bacteria, as well as the inflammatory and immune mediator interleukin-1. Prevents the destabilization of lysosome membranes, thereby preventing proteolytic enzymes from accumulating in the inflammatory focus. Makes capillary walls less permeable. Reduces the activity of connective tissue cells in the body that synthesize the extracellular matrix. Suppresses the activity of phospholipase, which hydrolyzes the phospholipid acyl chain in the sn-2 position, resulting in a decrease in the concentration of proinflammatory and nociceptive mediators prostaglandins and mediators of allergy and inflammation leukotrienes. Prevents an increase in the concentration of COX. Reduces the number of lymphoid cells, phagocytes, acidophilic and basophilic granulocytes due to their movement from the blood to the lymph. Interferes with the synthesis of antibodies. When applied to the skin in the area of blood vessels, it exhibits a vasoconstrictor effect. It affects the metabolism of proteins, fats and carbohydrates: it activates the metabolic reactions of glucose formation from non-carbohydrate compounds, stimulates the absorption of amino acids by liver and kidney cells. Promotes the storage of glycogen by the liver, activating glycogen synthetase and the process of glucose formation from protein compounds. Prevents the absorption of glucose by adipocytes - adipose tissue cells. Promotes the accumulation of sodium ions and water in the body, and the elimination of potassium ions from the body. Prevents the absorption of calcium in the gastrointestinal tract, removes calcium ions from bone tissue and enhances their elimination along with urine. Exhibits a catabolic effect in peripheral tissues. When used locally (externally), the ability of the drug to achieve a therapeutic effect is due to its anti-inflammatory, antiallergic, vasoconstrictor (as a result of which exudation is suppressed) effect.
The anti-inflammatory potential of Beloderm Express is thirty times greater than that of hydrocortisone. The drug has no affinity for mineralocorticoid receptors. After application to the skin, about 12-14% of the dose used is absorbed into the systemic bloodstream (to a lesser extent when applied to intact skin, to a greater extent when used in an area of inflammation or applied under an airtight bandage). Beloderm Express is prescribed for skin diseases of various origins caused by both exogenous and endogenous causes, including eczematous skin lesions (coin-shaped, atopic, dyshidrotic eczema), infantile prurigo (prurigo), contact dermatitis, exfoliative dermatitis, pruritic lichenoid dermatitis, photocontact dermatitis , seborrhea, intertrigenous dermatitis, etc. The dose is selected by the doctor on an individual basis. Frequency of use: 2-6 times a day until the clinical picture improves, then 1-2 times a day. When using the drug in pediatric practice, as well as in persons with facial skin lesions, the duration of the medication course should be no more than five days. For viral and bacterial skin infections, as well as mycoses, the use of the drug is possible only under strict medical supervision. The same is true for patients in the post-vaccination period, as well as persons with diseases of the gastrointestinal tract (ulcerative-erosive lesions of the stomach and duodenum, inflammation of the mucous membrane of the esophagus, stomach, small intestine, etc.), and the cardiovascular system. If signs of skin irritation or individual intolerance appear, the use of Beloderm Express should be interrupted and appropriate symptomatic treatment should be carried out. When an infection occurs that has developed against the background of an existing disease, it is necessary to carry out antimicrobial therapy.
BELODERM EXPRESS SPRAY 0.05% 50ML
Beloderm® Express in spray form is preferable for use in acute forms of dermatosis, incl. accompanied by exudation (formation of weeping surfaces).
Long-term external use of Beloderm® Express on the facial skin is not recommended, because the development of rosacea, perioral dermatitis and acne is possible. The course of treatment should not exceed 5 days.
Beloderm® Express should not be used in the eye area due to the likelihood of the drug getting into the mucous membrane, which can contribute to the development of cataracts, glaucoma, fungal eye infections and exacerbation of herpetic infections.
With systemic and local use of GCS, visual disturbances may occur, in which case you should consult an ophthalmologist.
With prolonged treatment, when applied to large areas of the body surface, as well as in the armpits and inguinal folds, when using occlusive dressings, diapers, systemic absorption of GCS is possible.
Some areas of the body, such as the armpits, groin folds, where there is a kind of natural occlusion, are more at risk of developing stretch marks, so continuous use of the drug in these areas of the skin should be short-term (no more than 4 weeks).
If side effects occur, therapy should be discontinued and consult a doctor.
Application in pediatrics.
Use in children over 2 years of age is possible only under medical supervision. Children are more at risk of suppression of HPA function due to the use of topical corticosteroids than adults due to their larger body surface area to body weight ratio and, accordingly, increased absorption of the drug. In children, this is accompanied by low plasma cortisol levels and lack of response to ACTH stimulation. Itsenko-Cushing syndrome may occur, impaired growth and development, slower weight gain, increased ICP, manifested by protrusion of the fontanelle, headaches, and bilateral papilledema. Long-term use of the drug in children should be carried out according to strict indications and under the supervision of a physician. In children, more often than in adults, atrophic skin changes occur when GCS is used externally. The course of treatment should be limited to five days. Occlusive dressings should not be used.
Impact on the ability to drive vehicles and machinery.
There are no data on the effect of the drug on the ability to drive vehicles or use machinery.
Beloderm® Express
Beloderm® Express in spray form is preferable for use in acute forms of dermatosis, incl. accompanied by exudation (formation of weeping surfaces).
Long-term external use of Beloderm® Express on the facial skin is not recommended, because the development of rosacea, perioral dermatitis and acne is possible. The course of treatment should not exceed 5 days.
Beloderm® Express should not be used in the eye area due to the likelihood of the drug getting into the mucous membrane, which can contribute to the development of cataracts, glaucoma, fungal eye infections and exacerbation of herpetic infections.
With systemic and local use of GCS, visual disturbances may occur, in which case you should consult an ophthalmologist.
With prolonged treatment, when applied to large areas of the body surface, as well as in the armpits and inguinal folds, when using occlusive dressings, diapers, systemic absorption of GCS is possible.
Some areas of the body, such as the armpits, groin folds, where there is a kind of natural occlusion, are more at risk of developing stretch marks, so continuous use of the drug in these areas of the skin should be short-term (no more than 4 weeks).
If side effects occur, therapy should be discontinued and consult a doctor.
Application in pediatrics.
Use in children over 2 years of age is possible only under medical supervision. Children are more at risk of suppression of HPA function due to the use of topical corticosteroids than adults due to their larger body surface area to body weight ratio and, accordingly, increased absorption of the drug. In children, this is accompanied by low plasma cortisol levels and lack of response to ACTH stimulation. Itsenko-Cushing syndrome may occur, impaired growth and development, slower weight gain, increased ICP, manifested by protrusion of the fontanelle, headaches, and bilateral papilledema. Long-term use of the drug in children should be carried out according to strict indications and under the supervision of a physician. In children, more often than in adults, atrophic skin changes occur when GCS is used externally. The course of treatment should be limited to five days. Occlusive dressings should not be used.
Impact on the ability to drive vehicles and machinery.
There are no data on the effect of the drug on the ability to drive vehicles or use machinery.
